Cardiovascular & Metabolism Health
Cardiovascular & Metabolism Health
Connecting innovation with the needs of patients and healthcare systems
Cardiovascular and metabolic conditions represent a significant and growing global health challenge. Cardiovascular diseases remain the leading cause of mortality worldwide, while the number of people living with diabetes continues to rise.¹ ²
At Arcera Life Sciences, we believe progress depends on the ability to translate scientific innovation into sustainable access for patients across diverse healthcare environments.
Cardiovascular and metabolic diseases are closely interconnected and often share underlying risk factors. Conditions such as cardiovascular diseases, type 2 diabetes, obesity, hypertension and dyslipidemia highlight the complexity of cardiometabolic health and the importance of integrated approaches to prevention and long-term disease management.
Advances in scientific research and treatment are creating new opportunities to address these conditions. However, translating progress into better health outcomes also depends on early diagnosis, appropriate treatment, patient adherence and equitable access to medicines.
Cardiovascular and metabolic health is a focus therapeutic area for Arcera and an important part of our long-term portfolio development.
Our ambition is to build a differentiated cardiovascular and metabolic portfolio, strengthen our position in existing markets and expand our presence across new international markets. We aim to achieve this by combining innovative and proven medicines with strategic partnerships and the capabilities to successfully bring treatments to patients across diverse healthcare environments.


By continuously expanding our portfolio, strengthening our market presence and leveraging our international network and local expertise, we aim to create sustainable growth opportunities for our partners while broadening access to medicines that address important healthcare needs.
0+ brands
in our international portfolio
0+ countries
reached through our commercial network
0 million packs
delivered annually worldwide
This approach reflects a broader principle behind Arcera: bringing together international reach, local knowledge and long-term collaboration to help more patients live longer, healthier lives.
Scientific progress creates impact when it reaches the people who need it.
Bringing medicines to international markets means navigating different regulatory requirements, healthcare priorities, access environments and patient needs. Arcera combines international reach with local expertise to support medicines across their lifecycle.
Regulatory and medical expertise
Navigating regulatory requirements and supporting appropriate scientific and medical engagement across diverse markets.
Market access
Understanding local healthcare priorities and access environments to help make treatments available to patients.
Commercial excellence
Combining international scale with local market expertise and go-to-market execution to support effective commercialization.
Reliable supply and lifecycle management
Supporting continuity of supply and the long-term management of medicines throughout their lifecycle.
Innovation can come from anywhere. Bringing it to patients across diverse international markets requires the right partnership model.
Arcera partners with pharmaceutical and biotechnology companies to develop, manufacture and commercialize a broad range of innovative and proven medicines that address important healthcare needs across our international markets.



By combining our partners’ scientific innovation with Arcera’s regulatory, medical, market access, commercial and supply capabilities, we work to translate promising medicines into sustainable market opportunities and broader patient access.
Our flexible approach brings together our partners’ innovation with Arcera’s local expertise and international capabilities.
In cardiovascular and metabolic health, we continue to explore opportunities to complement our established portfolio with differentiated innovation and build partnerships designed to create sustainable value for patients, partners and healthcare systems.
Interested in partnering with Arcera?
The future of cardiometabolic care will be shaped by many factors, from prevention and earlier intervention to effective disease management and sustainable access to care.
The cardiometabolic landscape continues to evolve, with scientific advances creating new opportunities to address complex and interconnected health conditions.
For Arcera, this evolution reinforces the importance of a forward-looking portfolio, strong partnerships and the capabilities to support medicines across diverse international markets.
We remain committed to exploring opportunities that can translate scientific progress into sustainable access and meaningful value for patients, partners and healthcare systems.
References
1. Cardiovascular diseases, @World Health Organization (WHO), last accessed: November 17, 2026.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. Global diabetes data, @International Diabetes Federation (IDF), last accessed: November 17, 2026.
https://diabetesatlas.org/data-by-location/global/